Comparison of the Computed Tomography Findings in COVID-19 and Other Viral Pneumonia in Immunocompetent Adults: A Systematic Review and Meta-Analysis

Altmayer, Stephan; Zanon, Matheus; Pacini, Gabriel Sartori; Watte, Guilherme; Barros, Marcelo Cardoso; Mohammed, Tan-Lucien; Verma, Nupur; Marchiori, Edson; Hochhegger, Bruno

doi:10.2139/ssrn.3572873

Cited by 8 publications

(12 citation statements)

References 11 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be noted that the studies in our meta-analysis included patients between January and June 2020, a period with a high COVID-19 frequency (mean of 48.7%; range, 41.7–59.8%). Specificity is likely to decrease with lower COVID-19 frequency and increasing frequency of other viral lung infections such as influenza ( 30 ).…”

Section: Discussionmentioning

confidence: 99%

Diagnostic Performance of CO-RADS and the RSNA Classification System in Evaluating COVID-19 at Chest CT: A Meta-Analysis

Kwee

Adams

Kwee

2021

Radiology: Cardiothoracic Imaging

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Diagnostic Performance of CO-RADS and the RSNA Classification System in Evaluating COVID-19 at Chest CT: A Meta-Analysis

Kwee

Adams

Kwee

2021

Radiology: Cardiothoracic Imaging

View full text Add to dashboard Cite

“…Among other findings reticulations were commonly reported followed by atelectasis [ . Altmayer et al (2020) 6 also reported that a predominantly GGO pattern is more common to occur in COVID-19 as compared to a mixed pattern of GGO and consolidation in the non-COVID viral pneumonia. The least common pattern to occur between the two groups is usually the predominant consolidation pattern.…”

Section: Discussionmentioning

confidence: 98%

“…Similar chest radiograph findings are known to occur in various other diseases, like adenovirus infections and influenza. Surprisingly the hallmark GGO can occur in up to 26% of normal healthy - -----------------------------------------------------------------------------Received on 02-03-2021 Accepted on 21-05-2021 individuals [5][6] . It is crucial to have an accurate and rapid assessment of COVID-19 clinical severity for early detection, management and monitoring of disease process.…”

Section: Introductionmentioning

confidence: 99%

Investigation of HRCT Chest Severity in Patients with COVID-19: A Study of Tertiary Care Hospital in Pakistan

Sarfraz¹,

Waheed²,

Akhtar³

et al. 2021

PJMHS

View full text Add to dashboard Cite

Background: High-resolution computed tomography (HRCT) chest has a key role in diagnosis COVID-19, as it provides specific imaging features, i.e., bilateral, peripheral and sub-pleural, ground-glass opacity (GGO), consolidation and many associated findings. Aim: To provide the detailed chest HRCT findings along with clinical information in patients with COVID-19. Methods: A cross-sectional study was conducted in the Department of Radiology SZPGMI, Lahore. Information on clinical data, chest radiography appearance and comorbidities were recorded ona designed proforma. HRCT chest findings were recorded in terms of pattern, distribution, laterality, and other findings. HRCT chest severity was calculated using a 25 point CT severity score. Kendall’s Tau test applied to investigate the correlation between the severity of HRCT chest with clinical severity levels of COVID-19. Results: Fever (74%) was the most reported presenting symptom, followed by dry cough (70%). The majority of patients had abnormal chest X-ray (57%) as well as abnormal HRCT chest (90%). The majority of patients were in mild clinical scoring levels of disease (61%) and mild category (49%) of HRCT chest severity. In majority of the patients (46%), all five pulmonary lobes were involved, whereas the right lower lobe was most frequently affected. The pattern of ground-glass opacity (GGO) was found in 82% of patients. Most common distribution was ‘peripheral’, reported in 90% patients. Multiple lobe involvement was found in 82% of patients. The unilateral pulmonary involvement was observed in 12% of patients, whereas, bilateral was found in 78% of patients. Reticulations were reported in 22% followed by atelectasis in 18% patients. Conclusion: COVID-19 patients usually present with abnormal HRCT chest, mostly with a benign course. Multiple pulmonary lobes are commonly involved, especially basal lobes with ground glass opacities. Clinical severity of the disease is reflected in HRCT findings. Keywords: COVID-19 Pandemic, HRCT Chest Findings, Ground Glass Opacity (GGO), Consolidation

show abstract

“…Direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) is a blood purification therapy used to treat septic shock, 4 and acute respiratory diseases such as rapidly progressing interstitial pneumonia 5 and acute exacerbation of idiopathic pulmonary fibrosis. 6 COVID-19 pneumonia can also take the form of interstitial changes, 7 but few reports are available on the use of PMX-DHP therapy in patients with COVID-19 pneumonia.…”

Section: Introductionmentioning

confidence: 99%

PMX-DHP Therapy for Dyspnea and Deoxygenation in Severe COVID-19 Pneumonia: A Case Series

Kuwana¹,

Kinoshita²,

Hirabayashi³

et al. 2021

IDR

View full text Add to dashboard Cite

Hypercytokinemia induced by coronavirus disease-19 (COVID-19) is associated with severe pulmonary involvement, which may lead to respiratory failure. These conditions play an important role in the worsening of clinical symptoms in patients with severe COVID-19. There is no established treatment for hypercytokinemia. We report on two patients whose clinical symptoms improved after direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP), following the administration of the anti-inflammatory agent tocilizumab. Case A was a 70-year-old man diagnosed with COVID-19 pneumonia. Despite treatment with ciclesonide and favipiravir, supplemental oxygen was administered due to the worsening of dyspnea with tachypnea. Although tocilizumab was started on day 6, the patient deteriorated into deoxygenation, presenting with the PaO 2 /F I O 2 (P/F) ratio of 92. On days 8 and 10, the patient received PMX-DHP therapy. On day 11, his dyspnea improved. On day 13, his P/F ratio began to improve, and oxygen therapy was discontinued on day 18. The patient recovered without requiring mechanical ventilation. Case B was a 70-year-old man diagnosed with COVID-19 pneumonia and treated with favipiravir, starting on day 0. Despite starting ciclesonide inhalation and tocilizumab on day 2, his P/F ratio was 53. On day 5, he received PMX-DHP therapy. On day 6, his dyspnea improved, as did his P/F ratio, reaching 81 on day 8. Finally, his clinical symptoms resolved, and he was discharged from the intensive care unit without requiring mechanical ventilation. These cases indicate that PMX-DHP therapy might be a suitable treatment option for dyspnea and deoxygenation in COVID-19 pneumonia, especially in cases where an anti-inflammatory agent, such as tocilizumab, has failed to achieve the desired effect.

show abstract

Comparison of the Computed Tomography Findings in COVID-19 and Other Viral Pneumonia in Immunocompetent Adults: A Systematic Review and Meta-Analysis

Cited by 8 publications

References 11 publications

Diagnostic Performance of CO-RADS and the RSNA Classification System in Evaluating COVID-19 at Chest CT: A Meta-Analysis

Diagnostic Performance of CO-RADS and the RSNA Classification System in Evaluating COVID-19 at Chest CT: A Meta-Analysis

Investigation of HRCT Chest Severity in Patients with COVID-19: A Study of Tertiary Care Hospital in Pakistan

PMX-DHP Therapy for Dyspnea and Deoxygenation in Severe COVID-19 Pneumonia: A Case Series

Contact Info

Product

Resources

About